New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
05:38 EDTTRIBTrinity Biotech upgraded to Buy from Neutral at Roth Capital
Roth Capital upgraded Trinity Biotech to Buy citing higher expectations for the company's cardiac troponin market opportunity following the company's Q1 results. Roth raised its price target for shares to $30 from $28.
News For TRIB From The Last 14 Days
Check below for free stories on TRIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TRIB

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use